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Background: The 6-minute walk test evaluates the effect of pharmacologic intervention in adults with pulmonary
arterial hypertension (PAH) but, for reasons of compliance or reliability, may not be appropriate for children at all
ages. Thus, peak oxygen consumption (VO2, maximal exercise test) was used instead in a pediatric PAH trial
(STARTS-1) to evaluate pharmacologic intervention with sildenafil. This was the first large placebo-controlled trial to
use the peak VO2 endpoint in this population. Our working hypothesis was that, as with other populations,
percentage changes in peak VO2 in pediatric patients with PAH are reliable and are associated with changes in
other clinical endpoints.
Methods: Using data from the subpopulation of 106 patients who were developmentally and physically able to
perform exercise testing, all of whom were World Health Organization Functional Class (WHO FC) I, II, or III,
reliability was assessed using the intraclass correlation coefficient and Bland-Altman plot on screening and baseline
data. Relationships between percentage change in peak VO2 from baseline to end of treatment and other
endpoints were evaluated using correlation coefficients and regression analyses.
Results: The intraclass correlation was 0.79 between screening and baseline peak VO2, an agreement that was
supported by the Bland-Altman plot. Percentage change in peak VO2 correlated well (r ≥0.40) and showed
responsiveness to a physician global assessment of change and with change in WHO FC (for baseline classes I and
III). Percentage change in peak VO2 did not correlate with change in the Family Cohesion of the Child Health
Questionnaire (r= 0.04) or with a subject global assessment of change (r= 0.12). The latter may have been
influenced by child and parental-proxy response and instrument administration.
Conclusion: In pediatric PAH patients who are developmentally and physically able to perform exercise testing,
peak VO2 measurements exhibited good reliability and improvements that were associated with improvements in
certain other clinical endpoints, such as the WHO FC and a physician global assessment.
Trial registration: ClinicalTrials.gov identifier NCT00159913.Background
Pulmonary arterial hypertension (PAH) is a relatively
rare condition associated with high mortality [1]. It is
characterized by increased pulmonary vascular resist-
ance and pulmonary arterial pressure leading to right
ventricular failure and ultimately death [2]. It may be
inherited (heritable PAH [HPAH], classified as familial or
sporadic), develop spontaneously (idiopathic PAH [IPAH]),* Correspondence: joseph.c.cappelleri@pfizer.com
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reproduction in any medium, provided the oror occur in association with congenital heart defects, con-
nective tissue disease, or other causes (associated PAH
[APAH]) [3]. Oral sildenafil citrate (REVATIOW, Pfizer Inc,
New York, NY) has been found to be efficacious and gen-
erally well tolerated in the treatment of chronic PAH in
adults, both as disease-specific monotherapy and as add-on
to intravenous therapy with epoprostenol [4,5]. However,
safe and effective therapy to increase the functional cap-
acity, quality of life, and survival of pediatric patients with
PAH is also needed.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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verity and response to treatment is the 6-minute walk test,
which is based on improvements in submaximal exercise
capacity [6,7]. However, when the first large, multicenter,
randomized, double-blind, placebo-controlled clinical trial
to investigate the effectiveness of sildenafil treatment for
PAH in children who require treatment despite conven-
tional therapy was being designed (ClinicalTrials.gov:
NCT00159913) [8], many specialists believed that compli-
ance with the directions for the 6-minute walk test could
be difficult for children. Children may become uninter-
ested or demotivated by factors unrelated to PAH, which
could impact reliability of the test. Additionally, they may
walk at a variable pace, resulting in unreliable or unstable
measurements. Thus, for the design of the clinical trial, it
was decided to use formal cardiopulmonary exercise test-
ing that could be more readily standardized.
The ability to perform aerobic work is defined by peak
oxygen consumption (VO2) at maximal effort [9]. Peak
VO2 is a parameter of noninvasive cardiopulmonary ex-
ercise testing that is affected by age, sex, conditioning
status, disease, or medications. Its prognostic value in
terms of survival has been demonstrated in adult
patients with IPAH [10]. Thus, percentage change from
baseline to end of treatment in peak VO2 was selected
as the primary efficacy endpoint in the controlled clin-
ical trial of sildenafil treatment for PAH in children,
making it the first trial of its kind with the potential to
evaluate the correlation between changes in peak VO2
and other clinical endpoints [8].
The aim of this paper is to investigate the measure-
ment properties of peak VO2 in terms of its associations
with other clinical endpoints and its reliability. It was
hypothesized that, as observed with other populations,
percentage changes in peak VO2 in pediatric patients




The data set was derived from the Sildenafil in Treat-
ment-naive children, Aged 1–17 years, with pulmonary
arterial hypertension (STARTS-1) trial, a multinational
trial of sildenafil citrate with a 16-week, double-blind,
placebo-controlled treatment phase [8]. Pediatric patients
(aged 1–17 years) weighing ≥8 kg were included if they
had IPAH, HPAH, or APAH associated with congenital
heart defects or connective tissue disease. PAH (defined
as mean pulmonary artery pressure ≥25 mmHg at rest,
pulmonary capillary wedge pressure ≤15 mmHg [or
mean left atrial pressure ≤15 mmHg or left ventricular
end-diastolic pressure ≤15 mmHg], and as pulmonary
vascular resistance index ≥3 Wood units ×m2) was
confirmed by right heart catheterization at baseline.Concurrent medication remained stable throughout the
trial except for changes made for safety reasons. Nitrates,
cytochrome P450 3A4 inhibitors, prostacyclin analogues,
endothelin receptor antagonists, phosphodiesterase type
5 inhibitors (other than study medication), and arginine
supplements were not allowed.
The trial was conducted in compliance with the ethical
principles of the Declaration of Helsinki. The final
protocol, any amendments, and informed consent docu-
mentation were reviewed and approved by the Institu-
tional Review Boards and/or Independent Ethics
Committees at each of the investigational centers par-
ticipating in the study.a Written informed consent was
obtained from each child’s legal guardian and assent
from each child when applicable.
Patients were stratified by developmental ability to per-
form cardiopulmonary exercise testing (bicycle ergom-
eter) and by weight. Dosage of sildenafil was dependent
on weight and doses were selected to achieve maximum
plasma concentrations of 47 (low dose), 140 (medium
dose), and 373 (high dose) ng/mL at steady state [8]. The
8-kg to 20-kg group was randomized 1:2:1 to sildenafil
medium (10 mg) and high (20 mg) doses and placebo, re-
spectively. The >20-kg to 45-kg group was randomized
1:1:1:1 to sildenafil low (10 mg), medium (20 mg), and
high (40 mg) doses and placebo, respectively. The >45-kg
group was randomized 1:1:1:1 to sildenafil low (10 mg),
medium (40 mg), and high (80 mg) doses and placebo,
respectively. Study medication was administered 3 times
daily, ≥6 hours apart for 16 weeks. All patients rando-
mized to sildenafil received 10 mg 3 times daily for
1 week followed by titration to assigned dose. A total of
234 patients were randomized and treated, of whom 115
were developmentally and physically able to perform ex-
ercise testing.
The primary efficacy endpoint in the STARTS-1 trial
was percentage change in peak VO2 (normalized to body
weight), measured in mL/kg/min, from baseline to week
16 or end of treatment (at trough plasma concentrations
[before dosing or ≥4 h postdose]). Peak VO2 was assessed
by cardiopulmonary exercise testing in those who were
developmentally able to participate and achieved func-
tional capacity limits for peak VO2 of ≥10 mL/kg/min and
≤28 mL/kg/min at screening [8]. Other endpoints used in
the current correlational analyses included the following: a
physician global assessment of change (PGA) and a sub-
ject/parent global assessment of change (SGA), which are
7-point rating scales (“markedly improved,” “moderately
improved,” “mild improvement,” “no change,” “slightly
worse,” “moderately worse,” and “markedly worse”);
World Health Organization Functional Class (WHO FC,
in which FC I represents no limitation of physical activity,
FC II represents slight limitation, FC III represents
marked limitation, and FC IV represents inability to carry
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Family Cohesion domain of the parent form of the Child
Health Questionnaire [12].
Correlational analyses
The analysis plan was formed prospectively (before con-
ducting any analysis), with all analyses conducted in
SAS/STATW Version 8.2 (SAS Institute, Cary, NC). Ana-
lyses were based on peak VO2 data collected at baseline
and at the end of treatment.
Reliability
Reliability refers to the reproducibility of the measure-
ment when repeated at random in the same patient.
Patients whose peak VO2 status has not changed should
have a similar, or repeatable, response each time they are
assessed. If there is considerable variability, the measure-
ments are unreliable and results will be uninterpretable.
To assess test-retest reliability (stability), we examined
the strength of agreement between peak VO2 pretreat-
ment measurements at screening and baseline (up to
21 d after screening); no post-randomization data were
used. We calculated the intraclass correlation (ICC) along
with its confidence interval (CI), which estimates the pro-
portion of all variation that is not due to measurement
error [13,14]; a value ≥0.7 indicates acceptable reliability
[15]. We also calculated the Pearson correlation coeffi-
cient, which gauges the magnitude of the linear relation-
ship between the screening and baseline measurements.
In addition, we constructed a Bland-Altman plot, which
depicts agreement between screening and baseline mea-
surements [16].
Associations with Peak VO2
Associations were evaluated by calculating Pearson cor-
relation coefficients between the percentage change
(baseline to end of treatment) in peak VO2 and each of
following measures: the PGA; the SGA; change (baseline
to end of treatment) in WHO FC by baseline FC; and
change (baseline to end of treatment) in the Family Co-
hesion domain [12]. In sensitivity analyses, the corre-
sponding Spearman-rank correlation coefficients were
also examined.
For each of the prespecified correlational analyses,
three sets of Pearson correlations were calculated: (1)
pooled across treatment groups, (2) by treatment group
(placebo separate from all sildenafil groups combined),
and (3) partial, adjusting for (or partialing out) treat-
ment. Differences in results among them were noted. It
was hypothesized that associations would be meaningful
(≥0.40, consistent with a meaningful correlation [17]) be-
tween percentage change in peak VO2 and all of the
other measures except for change in the Family Cohe-
sion domain. Correlation coefficients less than 0.30 weretaken as less than meaningful [18]. Those between 0.30
and 0.40 were taken as ambiguous in their import.
Responsiveness
Responsiveness of measurement, a type of correlational
analysis, addresses the ability to detect change when a
particular patient improves or deteriorates. We assessed
this association by comparing percentage change (base-
line to end of treatment) in peak VO2 with change (base-
line to end of treatment) in the WHO FC (categorized
by baseline FC), the PGA, and the SGA. A regression
analysis was applied to examine each of those relation-
ships, with percentage change in peak VO2 serving as
the outcome or dependent variable and each of the other
measures serving as a separate predictor or explanatory
variable. In each bivariate analysis, a regression model
was fit in two ways: with the predictor taken as a
discrete categorical variable and as a continuous
variable.
Results
Of the 115 patients who were developmentally able to
perform exercise testing, 63% were girls, 36% had IPAH/
HPAH, and the remainder had PAH associated with con-
genital heart defects; no patient was in FC IV at baseline.
The mean ± standard deviation age was 12.7 ± 2.6 years
(range, 7–17 years, with 39 [46%] age 7–12 and 46 [54%]
age 13–17) in the combined sildenafil groups (n = 85),
and was 11.6 ± 2.5 years (range, 7–16 years, with 18
[60%] age 7–12 and 12 [40%] age 13–17) in the placebo
group (n = 30; Table 1). From this subgroup, 9 lacked
postbaseline data because of machine failure/damage
(n = 3), discontinuation without final assessment (n = 2),
and too ill, inadequate test data, lack of staff, and not
done in error (n = 1 each). Thus, 106 patients were evalu-
able for peak VO2 responses and provided data for the
psychometric analyses. WHO FC data were available for
104 evaluable patients at baseline (27 FC I, 56 FC II, 21
FC III).
Reliability
The estimated ICC between screening and baseline peak
VO2 was 0.79 (95% CI, 0.71–0.85; P < 0.0001), suggesting
good reliability (>0.70). The same estimate of 0.79 was
obtained from the Pearson correlation coefficient. Good
agreement between the screening peak VO2 and baseline
peak VO2 was also suggested by the Bland-Altman plot
(Figure 1), which indicated no relationship between the
difference in values across the 2 visits (which represents
measurement error) and the mean of values across the 2
visits (which represents the true value). These data not
only suggest that the data are reliable, but also support
the use of the average of the two measurements as the
baseline for statistical analyses.
Table 1 Demographic and baseline clinical characteristics





Female sex, n (%) 19 (63) 53 (62)
Age, y, n (%)
5–12 18 (60) 39 (46)
13–17 12 (40) 46 (54)
Race, n (%)
White 8 (27) 27 (32)
Black 2 (7) 1 (1)
Asian 4 (13) 20 (24)
Other 16 (53) 37 (44)
Weight, kg, mean (range) 37 (20–60) 40 (15–106)
BMI, kg/m2, mean (SD) 18 (3) 18 (4)
Peak VO2, mL/kg/min, mean (SD) 20.0 (3.7) 17.7 (4.2)
WHO functional class, n (%)
I 10 (33) 19 (22)
II 17 (57) 44 (52)
III 3 (10) 20 (24)
Missing 0 2 (2)
Etiology, n (%)
IPAH/HPAH 10 (33) 31 (36)
Surgical repair* 7 (23) 22 (26)
Congenital systemic-to-pulmonary
shunt (SaO2 ≥88% at rest)
12 (40) 30 (35)
Post-repair D-transposition of
great arteries
1 (3) 2 (2)
Mean pulmonary artery pressure,
mmHg, mean (SD)
58.7 (19.9) 68.4 (23.1)
Cardiac index, L/min/m2, mean (SD) 3.4 (1.4) 3.0 (1.1)
Pulmonary vascular resistance index,
dyns/cm5/m2, mean (SD)
1299 (775) 1871 (1232)
Mean pulmonary capillary wedge
pressure, mmHg, mean (SD)
10.0 (3.6) 9.7 (4.5)
Mean right atrial pressure, mmHg,
mean (SD)
8.3 (4.5) 8.4 (4.9)
BMI = body mass index; HPAH=heritable PAH; IPAH= idiopathic PAH;
n = sample size; PAH= pulmonary arterial hypertension; SaO2= systemic arterial
oxygen saturation; SD= standard deviation; VO2= oxygen consumption;
WHO=World Health Organization.
*Surgical repairs included atrial septal defect, ventricular septal defect, patent
ductus arteriosus, aortopulmonary window, and others.
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Across all treatment groups combined, Pearson correla-
tions of percentage changes in peak VO2 from baseline
with the PGA and with the change in WHO FC (with
baseline FC of I and III) correlated well (correlations of
≥0.40; Table 2). Correlations of percentage changes in
peak VO2 with the PGA depended on treatment group:
correlation of 0.49 (95% CI, 0.30–0.64; P< 0.0001; n = 77)for sildenafil doses combined and −0.11 (95% CI, –0.46 to
0.27; P=0.57; n = 29) for placebo. For patients with WHO
FC II or I at baseline, there was little (FC II) or no (FC I)
room for improvement in WHO FC. Thus, care needs to
be taken with the interpretation of their data. Across all
treatment groups combined, Pearson correlations of per-
centage changes in peak VO2 with changes in the Family
Cohesion domain score and with the SGA were 0.04 and
0.12, respectively (Table 2) Results from Spearman correla-
tions were very similar to those with Pearson correlations.Responsiveness
For each categorical improvement on the PGA, the
mean percentage change in peak VO2 increased by 8%
(assuming a linear relationship, with the PGA taken as
continuous; 95% CI, 4.6%–11.5%; P < 0.0001; Figure 2).
For each categorical improvement on the SGA, the
mean percentage change in peak VO2 increased by 2.2%
(assuming a linear relationship, with the SGA taken as
continuous; 95% CI, –1.3% to 5.8%; P= 0.21; Figure 3).
The mean percentage changes in peak VO2, which were
larger for higher improvement categories, were statisti-
cally significant for each of the three improvement cat-
egories of the PGA (7.2, 14.1, and 32.1; P < 0.01 for each)
and in the two highest improvement categories of the
SGA (9.8 and 11.9; P < 0.02 for each).
For the 27 patients with WHO FC I at baseline, there
was no room for improvement in FC: 3 of the 4 who dete-
riorated displayed a reduction in peak VO2 (Figure 4A).
None of the 56 patients with WHO FC II at baseline dete-
riorated and only 8 improved; 6 of the 8 had an increase
in peak VO2. Among all patients with WHO FC II at base-
line, mean percentage change in peak VO2 increased by
4.40% (95% CI, –7.3% to 16.1%; P = 0.45; Figure 4B). None
of the 21 patients with WHO FC III at baseline had a de-
terioration in WHO FC and 14 had an improvement, of
whom 12 had an increase in peak VO2. Among all patients
with WHO FC III at baseline, mean percentage change in
peak VO2 increased by 24.6% (95% CI, 5.1%–44.2%;
P=0.02) for a 1-category improvement in WHO FC
(Figure 4C).Discussion
In general, the results indicate that the peak VO2 has fa-
vorable measurement properties in pediatric patients
with PAH who are developmentally and physically able
to perform exercise testing. The magnitude of the correl-
ation of mean percentage change in peak VO2 with the
PGA was dependent on active or placebo treatment.
This is to be expected because the placebo group is
likely to have a more restricted range of values (which
represent measurement variability and random fluctua-
tions over time). In contrast, the active treatment group
Figure 1 Bland-Altman plot assessing the agreement between screening and baseline mean peak VO2.
Note: mean (standard deviation) difference = 0.23 (2.81). VO2 = oxygen consumptio7n.
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itional variability of individual treatment responses).
In a 16-week trial, it is not surprising that only
4 patients (all WHO FC I at baseline) reported deterior-
ation in WHO FC. The importance of this endpoint is in
the observance of improvement in WHO FC. However,
for the large proportion of patients who were WHO FC
I or II at baseline, there was no or limited room for im-
provement (unlike in WHO FC III patients). Eight of the
56 patients (14%) who were WHO FC II at baseline
improved, but 14 of 21 patients (67%) who were WHO
FC III at baseline improved. For these patients with
WHO FC III at baseline, there was a strong positive as-
sociation with percentage change in peak VO2.
It was unexpected that the percentage change in peak
VO2 would share a low correlation with the SGA, and itTable 2 Correlation of percentage change (baseline to end of
n Pearson correlation
Physician global assessment of change 106 0.41 (0.24 to 0
WHO FC
Baseline FC I* 27 0.40 (0.03 to 0
Baseline FC II* 56 0.10 (−0.17 to
Baseline FC III 21 0.52 (0.11 to 0
Family Cohesion domain 83 0.04 (−0.18 to
Subject global assessment of change 104 0.12 (−0.07 to
CI = confidence interval; Family Cohesion domain = Family Cohesion domain of the
WHO FC=World Health Organization Functional Class.
*For patients with WHO FC II or I at baseline, there was little (FC II) or no (FC I) room
interpretation of their data. For those with WHO FC I at baseline, only 4 patients de
deteriorated and 8 improved from baseline.may reflect influence by factors associated with child
and parental-proxy responses and with instrument ad-
ministration. A placebo response may have been
observed with the SGA, in which patients (regardless of
treatment group) are shifted toward a “mild improve-
ment” response whether or not peak VO2 improves. In
contrast, “markedly improved” on the SGA is unlikely to
be caused by a placebo response and most such patients
had clear improvement in peak VO2. This disparity can
impair the correlation. The low correlation between the
percentage change in peak VO2 and the SGA becomes
less surprising given that a post-hoc correlation between
PGA and SGA was not very high (0.39). The PGA corre-
lated well with the change in WHO FC in the subgroup
with baseline FC III but the SGA did not. The SGA is a
mixture of parent and patient (child) responses, thetreatment) in peak VO2 with other measures
(95% CI) P value Spearman correlation (95% CI) P value
.56) <0.0001 0.40 (0.22 to 0.55) <0.0001
.68) 0.04 0.41 (0.04 to 0.69) 0.03
0.36) 0.45 0.03 (−0.24 to 0.29) 0.84
.78) 0.02 0.61 (0.24 to 0.82) <0.01
0.25) 0.71 0.06 (−0.16 to 0.27) 0.57
0.31) 0.21 0.13 (−0.06 to 0.31) 0.19
Child Health Questionnaire [12]; n = sample size; VO2 = oxygen consumption;
for improvement in WHO FC. Thus, care needs to be taken with the
teriorated from baseline; for those with WHO FC II at baseline, none
Figure 2 Relationship of percentage change in peak VO2 with the physician global assessment of change. Percentage change in peak
VO2 was for baseline to end of treatment values. Physician global assessment of change was responded to at the end of treatment. Note: the
linear slope estimate, indicated by the straight line, was 8.0. A sensitivity analysis, which was performed excluding outliers, achieved similar results.
VO2 = oxygen consumption.
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the patient is young.
Conclusions
This pediatric PAH trial—the largest one to date—
offered the opportunity to evaluate peak VO2 as an end-
point with regard to its correlation with other clinical
endpoints, such as the WHO FC and the PGA. Peak
VO2 exhibited good reliability, and improvements wereFigure 3 Relationship of percentage change in peak VO2 with the sub
was for baseline to end of treatment values. Subject global assessment of c
slope estimate, indicated by the straight line, was 2.2. A sensitivity analysis,
VO2 = oxygen consumption.associated with improvements in certain other clinical
endpoints. Additional research should be conducted to
further elucidate the relationship between peak VO2 and
the SGA, to inform use of the SGA in this patient popu-
lation. This initial assessment of the measurement prop-
erties of peak VO2 suggests it is a robust measure with
utility as a primary endpoint in clinical trials for the
evaluation of the effect of drug treatment in pediatric
PAH.ject global assessment of change. Percentage change in peak VO2
hange was responded to at the end of treatment. Note: the linear
which was performed excluding outliers, achieved similar results.
Figure 4 Relationship of percentage change in peak VO2 with change in WHO FC. Percentage change in peak VO2 and change in WHO FC
was for baseline to end of treatment values. Patients with WHO FC I (A), WHO FC II (B), and WHO FC III (C) at baseline. Note: no improvement
was possible for patients with WHO FC I at baseline and improvement of only 1 FC was possible for patients with WHO FC II at baseline.
VO2 = oxygen consumption; WHO FC=World Health Organization Functional Class.
Cappelleri et al. BMC Pulmonary Medicine 2012, 12:54 Page 7 of 9
http://www.biomedcentral.com/1471-2466/12/54
Cappelleri et al. BMC Pulmonary Medicine 2012, 12:54 Page 8 of 9
http://www.biomedcentral.com/1471-2466/12/54Endnotes
aRoyal Children's Hospital Ethics in Human Research
Committee, Royal Children's Hospital, Parkville, VIC
AUSTRALIA; Comitê de Ética em Pesquisa do Instituto
Dante Pazzanese de Cardiologia, São Paulo, BRAZIL;
The Hospital for Sick Children Research Ethics Board,
Toronto, ON, CANADA; Health Research Ethics Board,
Biomedical Research, University of Alberta Walter
Mackenzie Health Science Centre, Edmonton, AB,
CANADA; Children's and Women's Health Centre of BC
Research Review Committee, Vancouver, BC, CANADA;
Clinical Research Ethics Board, Vancouver, BC, CANADA;
Comité Ético Científico Pediátrico, Santiago, CHILE;
Comité de Evaluación Etico Científico, Hospital Dr. Sótero
del Río Servicio de Salud Metropolitano Sur Oriente,
Santiago, CHILE; Comite de Etica en Investigacion -
Hospital Santa Clara – Empresa Social del Estado, Bogota,
Cundinamarca, COLOMBIA; Comite de Etica en Investi-
gacion Clinica - Fundacion Cardio Infantil, Instituto de
Cardiologia, Departmento de Investigaciones, Bogota,
Cundinamarca, COLOMBIA; Comite de Etica de la Clinica
Cardiovascular, Medellin, Antioquia, COLOMBIA; Con-
sejo Nacional de Investigacion en Salud, CONIS,
Ministerio de Salud, San Jose, COSTA RICA; UCIMED
Comite Etico Cientifico de la Universidad de Ciencias
Medicas, San Jose, COSTA RICA; Latin Ethics, Guatemala,
GUATEMALA; Medical Research Council Ethics Commit-
tee for Clinical Pharmacology, Budapest, HUNGARY; In-
stitutional Ethics Committee, CARE Foundation - CARE
Hospital, Hyderabad, Andhra Pradesh, INDIA; Research
and Ethics Committee, Amrita Institute of Medical
Sciences & Research Centre, Kochi, Kerala, INDIA; Comi-
tato Etico dell'azienda ospedaliera di Bologna – Policlinico
S.Orsola-Malpighi, Bologna, ITALY; Toho University
Omori Medical Center Institutional Review Board,
Ohta-ku, Tokyo, JAPAN; Joint Penang Independent Ethics
Committee, Clinical Research Center, Gleneagles Medical
Center, Penang, MALAYSIA; Comité de Bioética, Instituto
Nacional de Cardiologia "Dr. Ignacio Chavez", Mexico, DF,
MEXICO; Komisja Bioetyczna przy Instytucie, Pomnik
Centrum Zdrowia Dziecka, Warszawa, POLAND; Komisja
Bioetyczna Slaskiego, Uniwersytetu Medycznego w
Katowicach, Katowice, POLAND; Komisja Bioetyczna
Uniwersytetu Jagiellonskiego, Krakow, POLAND; Eth-
ics Committee at the Federal Service on Surveillance
in Healthcare and Social Development, Moscow,
RUSSIAN FEDERATION; The Ethics Committee
under Federal Agency of Quality Control Medicines,
Moscow, RUSSIAN FEDERATION; Regionala etik-
provningsnamnden i Lund, Lund, SWEDEN; Joint In-
stitutional Review Board, Taipei, TAIWAN; National
Taiwan University Hospital Ethics Committee, Taipei,
TAIWAN; Western Institutional Review Board, Olym-
pia, WA, UNITED STATES; Children's Hospital ofWisconsin, Milwaukee, WI, UNITED STATES; Chil-
dren's Research Institute, Human Subjects Research
Committee/CHRF Administration, Columbus, OH,
UNITED STATES; Stanford University Medical Center
Institutional Review Board, Stanford, CA, UNITED
STATES; Colorado Multiple Institutional Review
Board, Aurora, CO, UNITED STATES; Children's
Hospital Boston, Committee on Clinical Investigators,
Boston, MA, UNITED STATES; Washington Univer-
sity Medical Center Institutional Review Board,
Human Studies Committee, St. Louis, MO, UNITED
STATES; University of Michigan Institutional Review
Board – Medicine, University of Michigan Hospitals
and Health Systems, Ann Arbor, MI, UNITED
STATES; Children's Hospital Medical Center Institu-
tional Review Board, Seattle, WA, UNITED STATES;
Medical University of South Carolina, Office of Re-
search Integrity, Charleston, SC, UNITED STATES;
Vanderbilt University Institutional Review Board,
Nashville, TN, UNITED STATES.
Competing interests
Joseph C. Cappelleri, Lie-Ju Hwang, Jack Mardekian and Marko A. Mychaskiw
are employees of Pfizer Inc (USA), the manufacturer of sildenafil citrate.
Authors’ contributions
All authors participated in varying ways to the conception, design, analysis,
or interpretation of results; and to the drafting of the manuscript or to its
revision for important intellectual content. In addition, all authors read and
approved the final manuscript.
Acknowledgments
This study was sponsored by Pfizer Inc. The authors thank Gary R. Layton
and Helen Richardson for their valuable contribution to the design, analysis,
and interpretation of results; Hunter Gillies for clinical review of the
manuscript; Marjana Serdarevic-Pehar for contributions on the clinical
program for pulmonary arterial hypertension; and the BioMed Central
Editorial team, including Robert Tulloh and Ageliki Karatza. Additional
analyses were conducted by Daniela Negrini and Elaine Squire of Quanticate
Ltd (Hertfordshire, UK) and Kabir Quazi of Quintiles Canada (Saint-Laurent,
QC, Canada), and were funded by Pfizer Inc. Editorial/medical writing
support was provided by Deborah M. Campoli-Richards, BSPharm, RPh, of
Complete Healthcare Communications, Inc., and was funded by Pfizer Inc.
Author details
1Department of Statistics, Pfizer Inc, Groton, CT, USA. 2Department of
Statistics, Specialty Care Business Unit, Pfizer Inc, New York, NY, USA.
3Department of Outcomes Research, Specialty Care Business Unit, Pfizer Inc,
Collegeville, PA, USA.
Received: 27 February 2012 Accepted: 31 August 2012
Published: 10 September 2012
References
1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G,
Gibbs S, Lebrec D, Speich R, Beghetti M, et al: Clinical classification of
pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 suppl S):5S–12S.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM,
Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al: Cellular and
molecular pathobiology of pulmonary arterial hypertension. J Am Coll
Cardiol 2004, 43(12 suppl S):13S–24S.
3. Humbert M, Trembath RC: Genetics of pulmonary hypertension: from
bench to bedside. Eur Respir J 2002, 20(3):741–749.
Cappelleri et al. BMC Pulmonary Medicine 2012, 12:54 Page 9 of 9
http://www.biomedcentral.com/1471-2466/12/544. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T,
Parpia T, Burgess G, Branzi A, et al: Sildenafil citrate therapy for pulmonary
arterial hypertension. N Engl J Med 2005, 353(20):2148–2157.
5. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ,
Kramer MR, Burgess G, Collings L, et al: Addition of sildenafil to long-term
intravenous epoprostenol therapy in patients with pulmonary arterial
hypertension: a randomized trial. Ann Intern Med 2008, 149(8):521–530.
6. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW,
Berman LB: The 6-minute walk: a new measure of exercise capacity in
patients with chronic heart failure. Can Med Assoc J 1985, 132(8):919–923.
7. Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP: Estimating a
minimally important difference in pulmonary arterial hypertension
following treatment with sildenafil. Chest 2009, 135(1):137–142.
8. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK,
Pulido T, Layton GR, Serdarevic-Pehar M, et al: A randomized, double-blind,
placebo-controlled, dose-ranging study of oral sildenafil citrate in
treatment-naive children with pulmonary arterial hypertension.
Circulation 2012, 125(2):324–334.
9. Fleg JL, Pina IL, Balady GJ, Chaitman BR, Fletcher B, Lavie C, Limacher MC,
Stein RA, Williams M, Bazzarre T: Assessment of functional capacity in
clinical and research applications: An advisory from the Committee on
Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology,
American Heart Association. Circulation 2000, 102(13):1591–1597.
10. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R,
Hummel M, Hetzer R, Ewert R: Assessment of survival in patients with
primary pulmonary hypertension: importance of cardiopulmonary
exercise testing. Circulation 2002, 106(3):319–324.
11. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S:
Diagnosis and differential assessment of pulmonary arterial
hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):40S–47S.
12. Landgraf JM, Abetz L, Ware JE: The CHQ: A User’s Manual. 2nd edition.
Boston, MA: Health Act; 1999.
13. Lu L, Shara N: Reliability analysis: Calculate and compare intra-class correlation
coefficients (ICC) in SAS. NorthEast SAS Users Group (NESUG) 2007: Statistics
and Data Analysis; http://www.nesug.org/proceedings/nesug07/sa/sa13.pdf.
14. Lachin JM: The role of measurement reliability in clinical trials. Clin Trials
2004, 1(6):553–566.
15. Streiner D, Norman G: Health Measurement Scales: A Practical Guide to Their
Development and Use. 4th edition. New York, NY: Oxford University Press;
2008.
16. Bland JM, Altman DG: Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986,
1(8476):307–310.
17. Stevens J: Applied Multivariate Statistics for the Social Sciences. 4th edition.
Mahwah, NJ: Lawrence Erlbaum; 2002.
18. Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition.
Hillsdale, NJ: Lawrence Erlbaum; 1988.
doi:10.1186/1471-2466-12-54
Cite this article as: Cappelleri et al.: Assessment of measurement
properties of peak VO2 in children with pulmonary arterial
hypertension. BMC Pulmonary Medicine 2012 12:54.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
